Clinical Trial Update: Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating iparomlimab and tuvonralimab in combination with lenvatinib or axitinib for locally advanced or metastatic clear cell r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• Axitinib (Axitinib)
• Lenvatinib (lenvatinib)
• Tuvonralimab (tuvonralimab)
• iparomlimab

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: RCC, Renal Cell Cancer | Phase 2 | Status: NOT_YET_RECRUITING